SeQure Dx, Inc. – Trademark Portfolio
Entity Type: 03
SeQure Dx, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include SEQURE DX. The owner is based in Waltham, MA.
1440 Main Street, Suite 320
Waltham, MA 02451
Showing of trademarks Trademarks
Trademark Classifications
SeQure Dx, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does SeQure Dx, Inc. have?
SeQure Dx, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 abandoned.
What trademark classes does SeQure Dx, Inc. file in?
SeQure Dx, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are SeQure Dx, Inc.'s most well-known trademarks?
SeQure Dx, Inc.'s registered trademark portfolio includes well-known marks such as SEQURE DX. These are among 1 currently registered trademark in the portfolio.
What is SeQure Dx, Inc.'s trademark registration success rate?
SeQure Dx, Inc. has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.